Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

NCT04598919 is registered in ClinicalTrials.gov with National Jewish Health as lead sponsor.

NCT NCT04598919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04598919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Lead sponsor
National Jewish Health
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 12, 2020
Completion date
June 30, 2025
Enrollment
49 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis (ipf)